This study is to assess the use of Artificial intellignce (AI) to predict eye treatment changes in adult participants with diabetic macular edema (DME).
Previously untreated Diabetic macular edema (DME) Participants.
Baseline macular edema ≥350 microns confirmed on Spectralis Standard deviation (SD)-Optical coherence tomography (OCT) or equivalent.
Baseline Best corrected visual acuity (BCVA) between 23 and 78 Early treatment diabetic retinopathy study (ETDRS) letters (between 20/32 and 20/230 Snellen).
History of eyes with previous intravitreal or laser treatment for DME.
History of eyes with previous intraocular or periocular corticosteroid for DME.
History eyes with other macular disease, causing visual reduction or disturbance.